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ABSTRACTS 
Background: Obesity promotes the progression to microalbuminuria and increases 
the risk of chronic kidney disease. Current protocols of screening microalbuminuria 
are not recommended for the overweight or obesity.   
Design and Methods: A cross-sectional study was conducted. The relationship 
between metabolic risk factors and microalbuminuria was investigated. A regression 
model based on metabolic risk factors was developed and evaluated for predicting 
microalbuminuria in the overweight or obesity  
Results: The prevalence of MA was reached up to 17.6% in Chinese overweight men. 
Obesity, hypertension, hyperglycemia and hyperuricemia were the important risk 
factors of microalbuminuria in the overweight. The area under ROC curves of the 
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regression model based on the risk factors was 0.82 in predicting microalbuminuria, 
meanwhile, a decision threshold of 0.2 was found for predicting microalbuminuria with 
sensitivity 67.4% and specificity 79.0%, global predictive value of 75.7%; a decision 
threshold of 0.1 was chosen for screening microalbuminuria with sensitivity 90.0% 
and specificity 56.5%, global predictive value 61.7%.  
Conclusions: The prediction model was an effective tool for screening 
microalbuminuria by using routine data among overweight populations.  
   
Key Words: metabolism, obesity, microalbuminuria, chronic kidney disease, 
regression model 
 
Introduction 
Overweight or obesity is dramatically increasing in its incidence and prevalence, and 
has become a worldwide public health problem.1 The overall prevalence of overweight 
and obesity has increased to 53.4% in middle-aged and senior Chinese people.2 
Obesity is important in the genesis of diabetes mellitus, hypertension and 
cardiovascular disease, all of which increase the risk of chronic kidney disease 
(CKD).3 Recently, there is a growing evidence that obesity itself significantly increases 
CKD and accelerates its progression.4, 5  As a result, the absolute number of CKD 
may be disturbing among overweight or obese populations. Unfortunately, many 
overweight individuals are unaware of having CKD. So early screening of CKD for the 
overweight may be necessary.  
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Microalbuminuria(MA) is the earliest sign of CKD and is a predictor of the progression 
of CKD to the end-stage renal disease(ESRD).6 Currently, several screening 
strategies for detection of CKD have been proposed in the diverse population. For 
example, screening MA for all individuals with diabetes has been recommended by 
several international organizations.7, 8 It is also advocated to screen MA for people 
with hypertension and old.8-10 However, few recommendations have been present for 
the overweight. In this context, a routine, economical but comprehensive method to 
predict MA would be helpful to promote early awareness and better management of 
CKD among the overweight population. 
 
On the other hand, evidence from clinical studies indicated that metabolic disorder is 
already present at an early phase of renal damage. Those metabolic factors have 
been implicated in the pathogenesis of chronic kidney disease and some of them can 
be virtually used to estimate the risk of renal damage.11 For instance, high serum 
triglyceride(TG) and low high-density lipoprotein cholesterol(HDL-C) levels predict an 
increased risk of renal damage.12 In addition, elevated levels of blood pressure(BP), 
extra large abdominal circumference, and high plasma glucose level have been 
associated with an increased prevalence of both MA and CKD.13 Given the relative 
ease of measuring body mass index(BMI), fasting plasma glucose(FPG), BP, and 
lipid concentrations, and also their importance as risk factors of MA and CKD, we 
attempted to develop a logistic regression model based on these measurements to 
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identify individuals who not only have MA but also at greatest risk for CKD.  
 
Design and Methods 
Subjects The subjects were recruited from healthy volunteers who have participated 
in the health survey project launched in 2009. Participants used a self-report 
questionnaire to document the medical history, current medication, family history, 
clinical symptoms after they had an intimate knowledge of our study program. 
Participants who have cardiovascular disease, chronic kidney disease and chronic 
liver disease were excluded. The final study subjects have no clinically significant 
abnormalities and were not taking any medication known to affect renal function or 
lipid/glucose metabolism (such as corticosteroids and lipid/glucose-lowering 
drugs).This study was approved by the Ethics Committee of Medical College of 
Zhejiang University, and a written informed consent was obtained from each 
participant. 
 
Laboratory Methods A physical examination and collection of laboratory samples (a 
fasting blood specimen, spot morning urine specimen) were carried out at the 
healthcare center of the First Affiliated Hospital of Zhejiang University. Weight and 
height were measured without shoes or heavy clothing using an anthropometric scale. 
BMI was calculated. The subjects with BMI of 25 kg/m2 or greater, classified as 
overweight or obese by World Health Organization criteria,14 were informed to collect 
24-h urine of the next day and record the urine volume. BP was measured twice with 
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the subject seated for at least 10 minutes using a mercury sphygmomanometer. The 
mean of two measurements was recorded. Fasting blood sample was drawn in a 
vacuum tube. Spot morning urine sample was collected and immediately checked 
with a microscope. All samples of blood and urine collection were centrifuged within 
2h and immediately frozen to −70°C. The biochemical indices such as serum 
creatinine(sCr) and urine creatinine(uCr), blood urea nitrogen(BUN), blood uric 
acid(BUA), total cholesterol(TC), FPG, TG and HDL-C were measured by a 
biochemical auto-analyzer (Hitachi 7600, Japan). Glomerular filtration rate(GFR) was 
estimated by modified MDRD equation based on Chinese population.15 The equation 
is as follows: eGFR (ml/min per 1.73 m2) =186× Pcr-1.154 ×age-0.203× 0.742 (if female) 
×1.233 (if Chinese). Urine albumin was measured in a Beckman analyzer (Beckman 
Image, USA) by rate nephelometry.   
 
Variable definitions MA was defined as urine albumin extraction(UAER)of 30 
-300mg in a 24 h urine collection, urine albumin(UAlb) 20-200mg/dl in a single spot 
urine sample, or urine albumin/Creatinine ratio(UACR) of 20-200 mg/g for men in a 
single spot urine sample. These thresholds are recommended by KDIGO for detection 
of albuminuria.16  According to International Diabetes Federation(IDF),17 metabolic 
syndrome(MS) is defined as central obesity plus any two of the following: 
BP>=130/85mmHg; FPG>=5.6mmol/L; TG>1.7mmol/L; HDL-C <1.0mmol/L in men or 
<1.3mmol/L in women. In the present study, central obesity was defined as BMI>=25, 
instead of waist circumference. 
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Statistic analysis: 
The subjects were divided into two groups, namely the normalbuminuria and the 
microalbuminuria. The Student's t test was used to compare the differences between 
the two groups for continuous variables. The relationship of MA with demographic and 
metabolic variables was analyzed by univariate and multivariate logistic regression, 
and the odds ratios (OR) and confidence intervals (CI) for increased risk of MA were 
calculated. A forward stepwise multivariate logistic regression analysis was used to 
build the model for predicting the risk of MA. Meanwhile, the probabilities generated 
from the regression model were saved and used as new input variables to meet the 
requirement of receiver operating characteristic (ROC) curve analysis. UAER was 
used as the standard method to generate binomial variables. In order to evaluate the 
performance of the model predicting MA, the ROC curves of lipids ratio, eGFR, UAlb, 
UACR and the final model were generated, respectively, and their areas under ROC 
curve were compared with each other. In addition, the ROC curves were used to 
identify the optimal decision threshold through the Youden index. Sensitivity, 
specificity, positive predictive value, negative predictive value and global predictive 
value for the thresholds chosen were calculated. Analysis was performed using SPSS 
software version 15.0 (SPSS Inc. Chicago, IL). All P-values were 2-sided and a 
p-value of <0.05 was considered as statistical significance. 
 
RESULTS 
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Baseline characteristics of study subjects 
The study subjects consisted of 245 individuals classified as overweight or obesity.  
All participants were adult men with a mean age (±SD) of 44±13y (range, 20 to 76y) 
and a mean BMI (±SD) of 26.1±2.1kg/m2 (range, 24.5 to 40.2 kg/m2). Participants 
were divided into two groups according to the status of albuminuria, namely 
normalbuminuria and microalbuminuria. No macroalbuminuria was included. The 
demographic and metabolic characteristics of the participants are detailed in Table 1. 
The prevalence of MA in the overweight or obesity was 17.6% (43/245). The 
participants’ BMI, systolic pressure(SP), diastolic pressure(DP), FPG, TG, TC, BUA, 
uCr, UAlb, UACR and UAER differed significantly, while their age, HDL-C, LDL-C, 
TG/HDL-C, TC/HDL-C, LDL-C/HDL-C, BUN, sCr and eGFR were no statistically 
different between the two groups.  
 
The prevalence of abnormal metabolic components among overweight 
population 
Figure 1 shows the prevalence of components of MS, defined by the IDF criteria, 
among overweight population. Abnormal metabolism was highly prevalent in the 
overweight population. Of the subjects, 45.7% had hypertension, 18.2% had 
hyperglycemia, 57.6% had high TG and 40% had low HDL-C, and the prevalence of 
MS was 48.2%. 
 
Univariate and multivariate relationships between metabolic risk factors  
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with MA  
In univariate logistic regression analysis, MA was associated with BMI, systolic and 
diastolic BP, FPG, BUA, TG and TC concentrations (Table 2); age, BUN, sCr, eGFR, 
HDL-C and LDL-C concentrations were not correlated with MA. However, in 
multivariate logistic regression analysis, only BMI, FPG, SP and BUA were associated 
with the increased prevalence of MA, the other markers did not persist as 
independent risk factors of the increased prevalence of MA(Table 2). Among them, 
FPG was the strongest and independent risk factor. 
 
Development of the regression model for predicting MA 
Table 3 shows the results of the stepwise logistic regression analysis for the subjects. 
There were 4 variables used in the final prediction model, namely BMI, SP, FPG and 
BUA. Adjusted OR values of them were 1.30, 1.05, 3.22 and 1.01, respectively. 
Based on β regression coefficient of each variable, the Logistic regression equation 
was developed as follows:  
р= 1/[1+e-(-23.27+0.26*BMI +0.05*SP+1.17*FPG+0.01*BUA)] 
In this equation, р is the probability that a person is predicted to have MA, given 
independent variables BMI, SP, FPG and BUA. The corresponding regression 
coefficients of these variables were 0.26, 0.05, 1.17 and 0.01, respectively.  Given 
BMI=25, SP=130, FPG=5.6 and BUA=420, the response variable р is then equal to 
0.62, which indicates the person has about 62% chance of having MA. Traditionally, 
the logistic regression probability is given the default classification decision threshold 
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of 0.5, it is diagnosed as positive when the probability is greater than 50%. 
 
Comparison of areas under the ROC curves of lipids ratio, UAlb, UACR and the 
regression model in predicting MA. 
We performed ROC curves analysis for the regression model, UAlb, UACR and 
potential prediction markers (lipids ratio) in predicting MA. Their ROC curves were 
illustrated in Figure 2. Table 4 presents the areas under the ROC curves (AUC) of 
lipids ratio, UAlb, UACR and the regression model in predicting MA. According to a 
rough guide for classifying the accuracy of a diagnostic test, an area of 0.8-0.9 
represents a good test; 0.7-0.8 represents a fair test; 0.6-0.7 represents a poor test. In 
this study, the AUC of UAlb, UACR and the regression model were 0.87, 0.94 and 
0.82, respectively, all represented good tests, while the AUC of lipids ratio was less 
than 0.7, indicating poor test.  
 
Validation of UAlb, ACR and the regression model for Predicting MA among  
overweight or obese male population 
The traditional threshold to identify MA were the following values: UAlb of 20 mg/l or 
greater, UACR of 20 mg/g or greater for men, and the model of 0.5 or greater. 
Through the Youden index, the optimal threshold of 0.2 was found for the regression 
model to identify MA. Table 5 shows the results of applying these values to the study 
subjects. UAlb predicted MA with sensitivity 69.8% and specificity 93.1%, global 
predictive value of 89%. UACR predicted MA with sensitivity 79.1% and specificity 
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98%, global predictive value of 94.7%. The model predicted MA with sensitivity 67.4% 
and specificity 79.0%, global predictive value of 75.7% at the threshold of 0.2, with 
sensitivity 39.5% and specificity 97%, global predictive value of 86.1% at the 
threshold of 0.5. Additionally, through a linear interpolation, the threshold of 0.1 for the 
model was found to screen MA with sensitivity 90.0% and specificity 56.5%, global 
predictive value of 61.7%. 
 
Discussion 
Our goal was to develop a relatively simple approach allowing prediction of MA in 
overweight or obese persons based on some routinely available data. Early 
identification of high MA risk of may lead to more successful intervention and 
management of CKD, and is beneficial to prevent further renal damage.18 Our findings 
showed that predicting MA was feasible by using routine data, such as BMI, BP, FPG 
and BUA. These data can be easily obtained by physical examination and laboratory 
tests.  The potential clinical utility of our findings was highlighted by the evidence that 
17.6% of the overweight might have MA, and the absolute number of MA is 
considerable.  
 
Our results indicated that a considerable proportion of the overweight is accompanied 
by one or more metabolic disorders, including impaired glucose tolerance, 
dyslipidaemia and hypertension, all of which were the important components of 
metabolic syndrome(MS). In addition to increasing morbidity and mortality of 
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cardiovascular disease (CVD) and diabetes mellitus (DM),19 MS is strongly associated 
with the development of renal disease.11 It is evident that multiple metabolic disorders 
promote the progression of MA and CKD. Chandie Shaw PK and colleagues 
demonstrated that obesity was the most important contributor to the risk of MA and 
CKD in nondiabetic South Asians,20 Jing Chen revealed obesity and metabolic 
syndrome were related to MA and renal damage in Caucasians,13 In several epidemic 
investigations, hypertension, hyperglycemia and dyslipidaemia were also strongly 
correlated with MA and renal damage.21-23 Moreover, a recent study reported that 
BUA was the independent risk factor of MA.24 In agreement with those reports in the 
literatures, we identified a series of predictors including BMI, SP, FPG and BUA, 
predominantly contributed to the prediction of MA in the multivariable logistic 
regression model. Nevertheless, lipids did not have added value in our model. Our 
findings showed that plasma triacylglycerol levels was correlated to MA in univariate 
analysis, but not in multivariate analysis. Orchard TJ et al. also demonstrated the 
similar results in type 1 diabetes.25  However, some studies showed that high 
triacylglycerol concentration was an independent predictor for the risk of progression 
of renal damage.12, 26 This discrepancy could stem from lack of adequate statistical 
analysis, since triacylglycerol predicted progression of renal disease independently of 
BMI when individuals with normal BMI and microalbuminuria were pooled. In addition, 
our findings suggested that hyperglycaemia was the predominant risk factor, which 
indicated glycogenic control should be intensified for preventing MA and further renal 
damage, while the previous studies indicated obesity or hypertension was the most 
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important risk factor of MA.13, 20 Data regarding the effect of metabolic factors on MA 
are controversial.  It is possible that MA is associated with the race and ethnicity. 
Different population might confer different susceptibility on metabolic risk factors, and 
caused this discrepancy.27  
 
Our study data showed the prevalence of MA was relatively high in the overweight, 
which was consistent with the results from previous studies.28 The actual number of 
MA cases is disturbing. Although screening UACR has been been debated for use in 
the general population, it is currently still an opinion, far away from as a general 
practice.18, 29 Since an annual healthcare for the overweight or obese population is 
available, it is unacceptable that people with MA are not identified, thus miss the 
chance of early prevention of CKD, and suffer from ESRD in the end. Fortunately, 
nowadays there have been some efforts focusing on identifying the predictors of MA 
and preventing the progression of CKD. Currently, the standard method for identifying 
MA is UAER based on a 24h urine sample collection. UAlb and UACR are 
recommended to use as a screening tool for MA in the diabetes and hypertension. In 
this study, we identified four important predictors and developed the regression model 
for predicting the overweight subjects with and without MA. Compared to the gold 
standard of UAER, the model represented a good predicting test (AUC= 0.82), and a 
useful examination for screening MA in the overweight. At the traditional threshold, 
PPV of the model was greater than of UAlb, less than of UAER.  For specificity, the 
model had comparative performance versus UAlb and UACR in diagnosis of MA. 
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Furthermore, using the Youden index, we found the optimal threshold of the model for 
Chinese population. Compared with the traditional threshold, the model represented 
the optimal combination of sensitivity and specificity at the optimal threshold. For 
screening examination, more improvement is needed for sensitivity than specificity, so 
we chose a threshold of 0.1 for the model when sensitivity was 90% and specificity 
was 56.5%. With this threshold, 90% overweight persons with MA would be identified 
through the model, which would significantly reduce the proportion of missed MA. 
 
In addition to the regression model for predicting MA, the lipids profile was also used 
to predict MA in the present study. A previous study reported that TG/HDL-C ratio was 
an alternative method to identify overweight individuals with insulin resistance.30  
Another earlier study suggested TC/HDL-C ratio can be used as a predictor of 
cardiovascular Disease.31  In view of these positive data, we evaluated the 
performance of lipids ratio for predicting MA. Unfortunately, their performance was not 
ideal, and all areas of under ROC were less than 0.7(see Figure 2 and Table 4). 
 
The present regression model has some attractive features when compared with 
traditional screening tool, including UAlb and UACR. Our regression model is based 
on routine healthcare data, therefore, it is an inexpensive tools for health care 
professionals and perhaps epidemiologists in identifying the overweight individuals 
who are at the increased risk of MA and CKD. Moreover, the probability can be 
predicted by computer, and therefore, the model can be easily applied in clinical 
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practices. We would recommend offering the overweight individual a primary 
screening of MA by applying the routinely available data. If it is positive, the individual 
with MA can be discriminated through the detection of UAER. Current screening 
protocols are only recommended for the diabetics, hypertension and old individuals. 
Using current protocol, a considerable proportion of the overweight with MA won’t be 
identified sooner enough. 
 
There are several potential limitations in this study. First, the study subjects consisted 
of Chinese adult males. Therefore, the performance of the prediction model and 
thresholds for overweight females needs to be further investigated. Second, because 
of the cumbersome and error-prone nature of 24h urine collection, the present study 
is only a preliminary one.  A larger scale population investigation was recommended 
for the improvement of the prediction model in future.  
 
In conclusion, the prevalence of MA was relatively high, reaching up to 17.6% in 
Chinese overweight males. BMI, FPG, SP and BUA were the important predictors of 
MA and renal damage. The logistic regression model, including BMI, FPG, SP and 
BUA, was an effective tool of prediction MA for the overweight although it was not 
best tool compared to UACR and UAlb.  
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Table 1. Baseline characteristics of overweight or obese participants grouped by UAER 
Characteristics Normalbuminuria 
n=202 
Microalbuminuria 
n=43 
P-value 
Age( year) 42.94(0.89) 46.42(2.43) NS 
BMI(kg/m2) 25.83(0.14) 27.31(0.38) 0.001  
SP (mm/Hg)  125.88(0.83) 136.67(2.70) <0.001 
DP (mm/Hg) 77.25(0.54) 83.79(1.62) <0.001 
FPG(mmol/l)  5.06(0.04) 5.48(0.10) <0.001 
TG (mmol/l) 2.11(0.10) 2.76(0.25) 0.009 
TC (mmol/L) 4.86(0.06) 5.19(0.11) 0.026 
HDL-C (mmol/l) 1.08(0.02) 1.09(0.04) NS 
LDL-C (mmol/l) 2.49(0.05) 2.59(0.10) NS 
TG/HDL-C 2.20(0.14) 2.88(0.35) 0.045 
TC/HDL-C  4.64(0.08) 4.96(0.15) NS 
LDL-C/HDL-C  2.35(0.05) 2.43(0.09) NS 
BUN(mmol/l) 5.12(0.08) 5.16(0.17) NS 
BUA (umol/l) 368.85(5.67) 410.58(12.37) 0.002 
sCr(umol/l) 78.69(0.67) 81.86(2.02) NS 
eGFR(ml/min/1.73m2) 101.99(1.10) 97.71(2.99) NS 
UAlb (mg/l) 8.98(0.51) 59.81(11.28) <0.001 
uCr (umol/l) 17018.61(608.39) 13180.19(1413.74) 0.010 
UACR(mg/g) 5.11(0.29) 46.47(6.43) <0.001 
UAER(mg/24h) 6.31(5.31) 51.02(25.93) <0.001 
Data were expressed as mean (SE). NS, not significant.  
Normoalbuminuria: UAER<30 mg/24h; Microalbuminuria: 300 mg/24h>=UAER>=30 mg/24h. 
Participants with macroalbuminuria were excluded from this analysis. 
 
Table 2. Univariate and multivariate logistic regression relationships between MA and selected 
metabolic markers 
Markers Univariate OR(95% C.I) Multivariate Crude OR(95% C.I) 
Age( year) 1.02 (1.00-1.04) 1.05(0.99-1.12) 
BMI(kg/m2) 1.33(1.14-1.55)** 1.29 (1.10-1.51)** 
SP (mm/Hg)  1.06(1.03-1.09)** 1.03(0.98-1.08)* 
DP (mm/Hg) 1.09(1.05-1.13)** 1.04(0.97-1.11) 
FPG(mmol/l)  3.29(1.86-5.82)** 3.46(1.70-6.57)** 
TG (mmol/l) 1.29(1.06-1.57)* 1.20(0.50-2.69) 
TC (mmol/L) 1.51(1.05-2.19)* 0.73(0.08-8.88) 
HDL-C (mmol/l) 1.09(0.26-4.51) 2.25(0.14-49.23) 
LDL-C (mmol/l) 1.26(0.77-2.07) 1.53(0.08-18.78) 
BUN(mmol/l) 1.03(0.77-1.37) 1.04(0.72-1.52) 
BUA (umol/l) 1.01(1.00-1.01)** 1.01(1.00-1.01)* 
sCr(umol/l) 1.03(1.00-1.06) 1.21(1.00-1.46) 
eGFR 0.98((0.96-1.0) 1.12(0.99-1.27) 
OR, odds ratio; C.I, confidence interval. Crude OR was estimated by logistic regression 
analysis without adjustments. 
*p<0.05; **p<0.01 
 
Table 3. Multi-step logistic regression models for having MA 
Markers β Standard error Multivariate Adjusted  
OR(95% CI) 
P-Value 
BMI(kg/m2) 0.26 0.08 1.30(1.11-1.52) 0.001 
SP (mm/Hg)  0.05 0.01 1.05(1.02-1.08) 0.001 
FPG(mmol/l)  1.17 0.33 3.22(1.71-6.05) <0.001 
BUA (umol/l) 0.01 0.00 1.01(1.00-1.01) 0.004 
Constant -23.27 3.60 0.00 <0.001 
OR, odds ratio; C.I,confidence interval.  Adjusted OR was adjusted for age, DP, lipids, BUN 
and sCr, eGFR.  β indicated regression coefficient 
 
Table 4. Comparison between the areas under the ROC curve constructed from output 
probabilities of lipids ratio, regression model and UAlb, UACR  
Markers AUC± SE 95% CI P-Value 
TG/HDLC 0.62±0.05 0.41-0.60 0.013 
TC/HDLC 0.61±0.04 0.41-0.60 0.029 
LDLC/HDLC 0.57±0.05 0.41-0.60 NS 
Model 0.82±0.04 0.75-0.89 <0.001 
UAlb 0.87±0.04 0.80-0.94 <0.001 
UACR 0.94±0.03 0.89-1.00 <0.001 
SE, standard error; C.I, confidence interval;  NS, not significant. 
 
Table 5. Performance of UAlb, UACR and the model for predicting MA at several cut-points in 
the study subjects  
Markers  cut-points Sensitivity (%) Specificity (%) PPV(%)  NPV(%) GPV(%) 
UAlb 20 69.8 93.1 68.2 93.5 89.0 
UACR 20 79.1 98.0 89.5 95.7 94.7 
Model 0.5 39.5 97.0 73.9 88.2 86.1 
0.2 67.4 79.0 40.8 91.9 75.7 
0.1 90.0 56.5 29.8 95.0 61.7 
PPV, positive Predictive Value;  NPV, negative Predictive Value; GPV, global predictive value  
 
  
 
 
Figure 1.  Prevalence of abnormal metabolic components according to IDF in the overweight 
/obesity. Bars are the estimated percentage of abnormal metabolic components. The 
prevalence of MS was 48.2% (118/245). Of all participants, 45.7% (112/245) had hypertension, 
18.4% (45/245) had hyperglycemia, 57.6% (142/245) had high TG and 40%(98/245) had low 
HDL-C. 
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Figure 2. Comparison, in individuals with overweight or obesity , of relationships between rates 
of true-positive test results (sensitivity) and false-positive test results (1 - specificity) for lipids 
ratio, UAlb, UACR and the regression model. 
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